Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat early Alzheimer's disease (AD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today